Liberty Biopharma Announces Initial Case for Erectile Dysfunction
October 11, 2016 - Richmond, British Columbia: Liberty Biopharma Inc. ("Liberty" or "Company") is pleased to announce the initial application of its regenerative microisolate from autologous adipose tissue ("RMAAT"), for the treatment of erectile dysfunction caused by atherosclerosis, or hardened penile arteries from normal aging.
The procedure was conducted with informed patient consent and the patient reported to the Company that there were no adverse events from the therapy.
Intracavernosal injection therapy for erectile dysfunction are potentially for patients who do not respond to oral drug therapies such as CialisTM or ViagraTM. CialisTM and ViagraTM are registered trademarks for Eli Lilly and Company and Pfizer Inc., respectively.
The Company invites researchers and clinical specialists interested in intracavernosal injection therapy and injection therapy around the prostates plexus nerves, after nerve-sparing radical prostatectomy, to contact Liberty Biopharma Inc.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "likely", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
For further information, please contact:
Liberty Biopharma Inc.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 604-377-7575
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly